1. Home
  2. VAL vs IMVT Comparison

VAL vs IMVT Comparison

Compare VAL & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valaris Limited

VAL

Valaris Limited

HOLD

Current Price

$93.54

Market Cap

6.3B

Sector

Energy

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$24.37

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VAL
IMVT
Founded
1975
2018
Country
Bermuda
United States
Employees
5642
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.4B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
VAL
IMVT
Price
$93.54
$24.37
Analyst Decision
Hold
Buy
Analyst Count
5
9
Target Price
$63.50
$30.78
AVG Volume (30 Days)
1.4M
920.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$15.62
N/A
P/E Ratio
$16.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.15
$12.72
52 Week High
$102.20
$29.25

Technical Indicators

Market Signals
Indicator
VAL
IMVT
Relative Strength Index (RSI) 61.64 34.88
Support Level $45.71 $21.74
Resistance Level $102.20 $24.63
Average True Range (ATR) 3.96 1.15
MACD -1.32 -0.30
Stochastic Oscillator 61.70 0.00

Price Performance

Historical Comparison
VAL
IMVT

About VAL Valaris Limited

Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: